Reviewing the progress of the biosimilars that could help answer the cost questions that are underpinning ASCO discussions

Healthcare systems around the globe are struggling to afford cancer drugs.

That is an admission made by a UK charity, which cites the rising costs of oncology medicines as increasingly unsustainable not just in Britain but in the USA and other countries too1.

With the American Institute of Cancer Research putting the cost of cancer – including drugs, diagnosis, radiotherapy and other treatments as well as end-of-life care – at about $895 billion a year, more than any other disease, working out how healthcare systems might afford the innovative new drugs which will be subject to data presentations at this year’s ASCO, will be a subtext to many discussions.